Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of subcutaneous BMS-945429 with or without methotrexate in moderate to severe rheumatoid arthritis after inadequate response to methotrexate
NL-OMON38282Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clazakizumab in rheumatoid arthritis (RA) (6 arms), sponsored by Bristol Myers Squibb. Started Aug 2011; status: active, not recruiting.
02
Drugs
clazakizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON38282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38282.